This course provides the most up to date information about prevention, recognition and emergency treatment of anaphylaxis, including information about adrenaline (epinephrine) autoinjectors and ASCIA Action Plans for Anaphylaxis.
First developed in 2011, the course is reviewed each year by the Australasian Society of Clinical Immunology and Allergy (ASCIA), the peak professional body of allergy and immunology in Australia and New Zealand.
Now available Version 7.1: 6 February 2021
Penicillin allergy is the most common drug allergy and is self-reported in up to 18 percent of hospitalised patients. However, most (up to 90%) of patients with a penicillin allergy label are found not to be allergic on further assessment. Importantly, in the true allergic patients, penicillin allergy can be life-threatening.
This course covers key questions about patients who have a history of penicillin allergy.
The aim of this course is to provide an evidence-based overview of eczema (atopic dermatitis) in children to promote accurate and consistent information for best practice management.
This course uses the term “eczema” to be consistent with resources for patients, consumers and carers.
This has been developed by the Australasian Society of Clinical Immunology and Allergy (ASCIA) and the National Allergy Strategy to provide ready access to accurate and consistent food allergy prevention education for health professionals throughout Australia and New Zealand, at no charge.
The course has included an extensive review process involving ASCIA members as well as representatives from other medical organisations throughout Australasia.